Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—Update From PACIFIC
J Thorac Oncol 2019 Oct 14;[EPub Ahead of Print], JE Gray, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, A Chiappori, KH Lee, BC Cho, D Planchard, L Paz-Ares, C Faivre-Finn, JF Vansteenkiste, DR Spigel, C Wadsworth, M Taboada, PA Dennis, M Özgüroğlu, SJ AntoniaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.